ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,281 to 4,300 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
FFR Guided PCI vs CABG: Number of Participants Experiencing Stroke7 of 755

8 of 741

-0.2 points

-1.3 to 1.0

1,496NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

FFR Guided PCI vs CABG: Number of Participants Experiencing Acute Kidney Injury1 of 755

7 of 741

-0.8 points

-1.8 to -0.0

1,496NCT02100722

A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease

D2S Intervention vs Usual Care: Timely Viral Suppression309 of 601

352 of 893

12.0 points

6.9 to 17.1

1,494NCT05140421

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

D2S Intervention vs Usual Care: deaths from any cause119 of 601

121 of 893

6.3 points

2.4 to 10.2

1,494NCT05140421

Testing a Novel Data-to-Suppression (D2S) Intervention Strategy in the Ryan White HIV/AIDS Program

FIRMAGON vs GnRH Agonist: deaths from any cause141 of 1,000

72 of 493

-0.5 points

-4.5 to 3.1

1,493NCT01234350

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

FIRMAGON vs GnRH Agonist: serious adverse events236 of 1,000

144 of 493

-5.6 points

-10.5 to -0.9

1,493NCT01234350

A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON

Varenicline vs Placebo: serious adverse events28 of 751

16 of 742

1.6 points

-0.2 to 3.4

1,493NCT01370356

A Study To Evaluate The Efficacy And Safety Of Varenicline Compared To Placebo For Smoking Cessation Through Reduction

Dose-Escalated Radiation Therapy Alone vs Dose-Escalated Radiation Therapy and Short-Term Androgen-Deprivation: deaths from any cause119 of 750

100 of 742

2.4 points

-1.2 to 6.0

1,492NCT00936390

Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer

PLWHIV With COVID-19 Cases vs PLWHIV Without COVID-19 Controls: Chronic Kidney Disease38 of 500

32 of 992

4.4 points

2.0 to 7.2

1,492NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

PLWHIV With COVID-19 Cases vs PLWHIV Without COVID-19 Controls: Chronic Obstructive Pulmonary Disease36 of 500

43 of 992

2.9 points

0.4 to 5.7

1,492NCT05481216

HIV-1 & Coronavirus-Coinfection in Europe: Morbidity & Risk Factors of COVID-19 in People Living With HIV

TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Disease-Free Survival Events287 of 745

333 of 746

-6.1 points

-11.1 to -1.1

1,491NCT00688740

Docetaxel in Node Positive Adjuvant Breast Cancer

TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Overall Survival Events188 of 745

241 of 746

-7.1 points

-11.6 to -2.5

1,491NCT00688740

Docetaxel in Node Positive Adjuvant Breast Cancer

TAC (Docetaxel) vs FAC (5-fluorouracil): Number of Participants With Second Primary Malignancies (Toxicity)67 of 745

66 of 746

0.1 points

-2.8 to 3.1

1,491NCT00688740

Docetaxel in Node Positive Adjuvant Breast Cancer

FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 6, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 684 of 738

46 of 750

5.2 points

2.4 to 8.2

1,488NCT03271021

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

FMX101, 4% Minocycline Foam vs Vehicle Foam: Investigator Global Assessment (IGA) Treatment Success (Dichotomized as Yes/no) at Week 12, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline199 of 738

133 of 750

9.2 points

5.0 to 13.4

1,488NCT03271021

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

FMX101, 4% Minocycline Foam vs Vehicle Foam: IGA Treatment Success (Dichotomized as Yes/no) at Week 9, Where Success is Defined as an IGA Score of 0 or 1, and at Least a 2-grade Improvement (Decrease) From Baseline at the Interim Visit at Week 9137 of 738

79 of 750

8.0 points

4.5 to 11.6

1,488NCT03271021

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

Task-shifted Epilepsy Care Arm (TSC) vs Enhanced Usual Epilepsy Care Arm (EUC): 75% or Greater Reduction in Seizure Frequency as Determined by the Blinded Physician at 24 Months Follow-up Visit636 of 763

531 of 725

10.1 points

5.9 to 14.3

1,488NCT04290975

Bridging the Childhood Epilepsy Treatment Gap in Africa

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Composite of Major and Non-major Bleeding Events33 of 988

14 of 499

0.5 points

-1.5 to 2.3

1,487NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto, BAY59-7939) vs Vitamin K Antagonist (VKA): Number of Participants With Major Bleedings as Per Central Adjudication6 of 988

4 of 499

-0.2 points

-1.5 to 0.7

1,487NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Rivaroxaban (Xarelto; BAY59-7939) vs Vitamin K Antagonist: serious adverse events93 of 988

38 of 499

1.8 points

-1.3 to 4.6

1,487NCT01674647

Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=215"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=215

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02100722-07d64fcb",
        "title": "FFR Guided PCI vs CABG: Number of Participants Experiencing Stroke",
        "summary": "7 of 755 against 8 of 741; risk difference -0.2 points, 95% interval -1.3 to 1.0; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
        "record": "/library/comparisons/NCT02100722-07d64fcb",
        "nct_id": "NCT02100722",
        "kind": "outcome",
        "participants": 1496,
        "risk_difference": {
          "value": -0.0015246981437291637,
          "lower": -0.01293300885823011,
          "upper": 0.009572898130875111
        },
        "group_1": "7 of 755",
        "group_2": "8 of 741",
        "difference": "-0.2 points",
        "interval": "-1.3 to 1.0",
        "trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
      },
      {
        "id": "NCT02100722-b9e3a38f",
        "title": "FFR Guided PCI vs CABG: Number of Participants Experiencing Acute Kidney Injury",
        "summary": "1 of 755 against 7 of 741; risk difference -0.8 points, 95% interval -1.8 to -0.0; NCT02100722, A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease",
        "record": "/library/comparisons/NCT02100722-b9e3a38f",
        "nct_id": "NCT02100722",
        "kind": "outcome",
        "participants": 1496,
        "risk_difference": {
          "value": -0.008122190345961695,
          "lower": -0.01810525273603738,
          "upper": -0.00028984580425778055
        },
        "group_1": "1 of 755",
        "group_2": "7 of 741",
        "difference": "-0.8 points",
        "interval": "-1.8 to -0.0",
        "trial_title": "A Comparison of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery in Patients With Multivessel Coronary Artery Disease"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=216",
  "request_id": "8b9-n51YO8R9GaSI"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Instruments

The conductscience.com catalog

One instrument from the ConductScience store with the tests, measures and species it is used for, the papers that used it, and the MeSH topics of those papers.

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

Diseases

Open Targets

One disease with the drugs studied for it, the targets those drugs act on, and the trials that study it, with their comparisons and papers.

Companies

ClinicalTrials.gov

One company with the trials it leads or helps run, the drugs those trials test, the conditions they study and the organizations it runs them with.

Cell lines

Cellosaurus

One cell line with the problems Cellosaurus records for it, its relatives, the cell banks that hold it, and the papers that used it.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?